Geron Corp (NASDAQ:GERN)
| Market Cap | 760.20M-14.5% |
| Revenue (ttm) | 204.56M+24.4% |
| Net Income | -69.89M+20.6% |
| EPS | -0.10+25.4% |
| Shares Out | 641.52M |
| PE Ratio | n/a |
| Forward PE | 16.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,554,684 |
| Open | 1.22 |
| Previous Close | 1.20 |
| Day's Range | 1.18 - 1.22 |
| 52-Week Range | 1.04 - 2.01 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 5.89(+397.05%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About GERN
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GERN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GERN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GERN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GERN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GERN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product revenue, net | $57.47M | 99.99% |
| Royalties | $7.00K | 0.01% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GERN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GERN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GERN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $30.47M |
| XBIState Street SPDR S&P Biotech ETF | $22.88M |
| IWMiShares Russell 2000 ETF | $17.47M |
| VXFVanguard Extended Market ETF | $9.30M |
| IWOiShares Russell 2000 Growth ETF | $6.34M |
| IBBiShares Biotechnology ETF | $5.77M |
Estimated from each fund’s disclosed top holdings × AUM
GERN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GERN’s recent data — informational, not investment advice